New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:21 EDTPATH, ENDP, TEVANuPathe up 36% to $4.40 after receiving rival Teva bid
Teva (TEVA) offered to purchase any and all of the shares of NuPathe (PATH) for $3.65 per share, net to the seller in cash, plus contractual rights to receive up to an additional $3.15 per share in contingent cash consideration payments payable in the future upon achievement of certain milestones related to NuPathe's migraine treatment ZECUITY. In December, Endo Health Solutions (ENDP) entered into a definitive agreement to acquire NuPathe for $2.85 per share in cash plus rights to receive additional cash payments of up to $3.15 per share based on net sales of ZECUITY. Shares of NuPath are up about 36% in pre-market trade following its disclosure of the rival bid made by Teva.
News For PATH;TEVA;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 15, 2015
17:08 EDTENDP, TEVASoros Fund gives quarterly update on stakes
Subscribe for More Information
09:31 EDTTEVAAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTTEVATeva migraine treatment data positive, says Bernstein
Subscribe for More Information
08:04 EDTTEVATeva to present new respiratory data at 2015 ATS conference
Teva Pharmaceutical Industries announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19.Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir RespiClick inhalation powder, which gained approval from the U.S. FDA in March 2015. ProAir RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler in adolescent and adult patients with asthma.
May 14, 2015
19:02 EDTENDPOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTENDPEndo, BioDelivery announces Phase 3 data for buprenorphine
Subscribe for More Information
08:35 EDTTEVATeva says data present case for TEV-48125 progression to Phase III
Subscribe for More Information
07:44 EDTTEVAInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
May 13, 2015
08:02 EDTTEVAANI Pharmaceuticals acquires rights to testosterone gel 1%
Subscribe for More Information
May 11, 2015
14:27 EDTTEVACowen recommends adding to both Teva and Mylan at current levels
Cowen recommends adding to both Teva (TEVA) and Mylan (MYL) at current levels. The firm continues to believe that a Mylan transaction will proceed despite some early contentious language, and all of Mylan's concerns will be resolved.
11:53 EDTTEVATeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
07:34 EDTENDPEndo acquires portfolio of branded and generic products from Aspen Holdings
Subscribe for More Information
07:13 EDTENDPEndo raises FY15 adjusted EPS to $4.40-$4.60 from $4.35-$4.55, consensus $4.48
Sees FY15 revenue $2.9B-$3B, consensus $2.99B. Sees FY15 adjusted gross margin of between 64%-65%. Sees FY15 effective tax rate of 13%-14%.
07:12 EDTENDPEndo reports Q1 US Branded Pharmaceuticals revenue $285M
Reports Q1 US Generic Pharmaceuticals revenue $357M. Reports Q1 International Pharmaceuticals revenue $73M.
07:11 EDTENDPEndo reports Q1 adjusted EPS $1.17, consensus $1.06
Subscribe for More Information
May 10, 2015
19:25 EDTTEVACourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
May 8, 2015
16:44 EDTTEVAMylan chairman says would consider buying Teva in the future, Reuters says
Subscribe for More Information
15:26 EDTTEVAMylan chairman says would consider buying Teva in the future, Reuters says
Subscribe for More Information
13:46 EDTTEVATeva looks to raise $25B to support Mylan bid, Bloomberg reports
Subscribe for More Information
12:38 EDTTEVATeva seeking $25B to finance bid for Mylan, Bloomberg reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use